Actinium Pharmaceuticals, Inc. (ATNM)
NYSEAMERICAN: ATNM · Real-Time Price · USD
1.205
-0.045 (-3.60%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Actinium Pharmaceuticals Stock Forecast
ATNM's stock price has decreased by -84.43% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Actinium Pharmaceuticals stock have an average target of 8.75, with a low estimate of 4.00 and a high estimate of 21. The average target predicts an increase of 626.14% from the current stock price of 1.21.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Actinium Pharmaceuticals stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +231.95% | Apr 1, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +231.95% | Mar 27, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +231.95% | Mar 25, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +231.95% | Mar 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +231.95% | Mar 18, 2025 |
Financial Forecast
Revenue This Year
32.94M
Revenue Next Year
47.94K
from 32.94M
Decreased by -99.85%
EPS This Year
-0.95
from -1.27
EPS Next Year
-1.14
from -0.95
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 61.1M | 98,700 | 48.9M | ||
| Avg | 32.9M | 47,940 | 18.0M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | -99.7% | 101,992.2% | ||
| Avg | - | -99.9% | 37,417.7% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.17 | -0.89 | -0.97 | ||
| Avg | -0.95 | -1.14 | -1.07 | ||
| Low | -1.46 | -1.40 | -1.13 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.